Timothy warned me about Toyotas several months ago, and this is his previous article with updates in the comments at the very end – scroll down. See also my previous article, M-m-m-my Toyota - featuring my first attempt at song writing, for my car of all things (thankfully not on the recall list!!). It goes to the tune of My Sharona. (Okay, I had some time on my hands.)
Timothy was subject to one of my interviews back in October, in case you missed it. - Ilene
All Toyota-produced vehicles sold in the U.S. today—including Toyota cars and trucks, and Lexus automobiles—are unsafe. It will take years before new models roll off the company’s assembly lines that are completely safe. Also, millions of Toyota vehicles are on American roads already that are unsafe to drive. Any recent-vintage Toyota product, model years 2002 and later, potentially can turn into a runaway vehicle at a moment’s notice. Driving one or being a passenger is like playing Russian roulette. Query whether Americans, especially young families with small children, will trust their lives to Toyota?
Tragically and irresponsibly, the company has lied for years and it is lying now. First, Toyota claimed it was a floor mat problem. Next, the problems were related to the accelerator pedal; and on and on the company’s lies go. Toyota has had 10 years to investigate these issues, and determine and implement solutions, but its management has lied repeatedly and it is still doing it. The runaway vehicle safety problems, which are confronting the giant automaker, are of a magnitude equal to or greater than those that brought down the storied Firestone tire brand, and the same thing may happen to Toyota. Every American needs to read about runaway Toyota-produced vehicles. The facts are sobering.
After the sudden-acceleration problems surfaced in Toyota and Lexus vehicles, the National Highway Traffic Safety Administration said “more motorists have died in Toyota vehicles associated with sudden acceleration in the last decade than in cars made by all other manufacturers combined.” Consumer advocate Ralph Nader’s trail-blazing and Herculean efforts helped launch the automobile safety movement. His speeches and writings on behalf of Americans (see, e.g., “Unsafe at Any Speed”) helped expose
It was much easier being an optimist before everyone else came around. As I said the other day, I no longer know what to think at this point (see: Now What?).
The data is all more constructive – Bill McBride (Calculated Risk) thinks we’re on the cusp of a major lift this coming year. But the expectations have already run off to the races at this point. Even ...
In case you weren’t aware, several of China’s major cities have experienced record-breaking, extremely dangerous levels of smog in recent days. For example, here is a shocking picture of Lianyungang, China:
Photograph: Chinafotopress/Getty Images.
So how did China’s state-run media decide to respond to this environmental and public health...
Unless you are part of the tiny portion of humanity that dotes on every utterance of the Federal Open Market Committee, you probably missed an important statement regarding the arcane world of "exce...
Stocks fell as investors reacted negatively to the adoption of the “Volcker rule”, which prohibits banks from proprietary trading.
The major stock indices took hard falls on Wednesday, as investors pondered the future of a stock market without proprietary trading by banks. Most stocks were in the red on Wednesday, after the Federal Reserve and four financial regulatory agencies adopted the so-called “Volcker rule”, named after former Fed Chair, Paul Volcker.
Although Volcker was not personally involved in writing the 71-page document, it resulted from Volcker’s insistence that the 2010 Dodd-Frank Act should include prohibitions on proprietary trading by banks, to prevent those institutions from taking on ex...
SHLD – Sears Holdings Corp. – Options volume on Sears today rose well above the average daily level for the stock during morning trading, with the bulk of the activity concentrated in far out of the money Jan 2014 expiry puts. Overall volume on the stock is approaching 30,000 contracts just before midday in New York, roughly 155% of SHLD’s average daily options volume of around 18,000 contracts. Shares in Sears are off 0.70% at $46.54 at present, off earlier session lows that saw the stock touch down to $45.98, the lowest level since September 5th.
Today, with very little market moving news, the S&P 500 closed at 1808.4, yet another new closing daily high. The index did touch the 1811 area on at least three distinctly different time slots creating a new resistance level. But after last week’s bevy of positive economic surprises, the sharp gain of 1.1% on Friday, leaving the index just a tiny point away from its ninth consecutive up week, we can’t be too quick to suggest today was a topping rally. For one thing, volume was quite low as traders seemed to be trying to sort out the odds on the earliest date of Fed tapering. Estimates range from this month to March and even later. But it’s going to happen…so why so much emphasis on when? Perhaps protection of end-of-the-year profits in so many fund managers portfolios? ...
Reminder: OpTrader is available to chat with Members, comments are found below each post.
This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).
We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options.
Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.
To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here...
These rallies are becoming familiar. In early July we saw a streak of 12 of 13 sessions in a row up, early September 11 of 12, and mid October 11 of 13 (current streak). It is a bit uncanny the similarities and how the escalator goes straight up in vertical ascent as we see indexes come out of mini corrections during QE. So we are about at the same stage where the last two began to tire, so it will be interesting if this is similar or if the current consensus of the market that there is nothing to worry about until next year as the Fed and D.C. are both off the table and this 3% annual growth rate in earnings we are now seeing in the S...
Welcome to the fouth update of the IRA Virtual Portfolio. First I am going to summarize the current state of the Portfolio then I will get into all the activity we had during September expiration.
Profit and Loss – Net of closed positions the portfolio is up a total of $769
Market Commentary – Last expiration I said, "I would like to put a total of $20,000 to work by the end of SEP expiration. If the VIX pops up to around 20 I plan to put about $50,000 total to work." The market didn't quite reach the goal but I did manage to deploy $15,000 of buying power. I still feel the market is too high and expect a correction during October. If the vix pops up to around 20 I still plan to put about $50,000 to work. If a correction doesn't happen I still plan to have a total of $25,000 in buying power put to work by October expiration. Now on to the act...
Reminder: Pharmboy is available to chat with Members, comments are found below each post.
Come and get it! Read all about it! Biotechs, biotechs and more biotechs to buy buy buy for your portfolio! To date, almost 30 biotech companies have hit the market. Most of the time, there are fewer than 10-12!
For the last five years, biotechs have had issues obtaining offer prices above expectations. In 2013, that trend looks to be broken. According to BiotechNow, the offer prices are 4% above expectations! In addition, biotechs are going public with little more than a wing and a prayer (pre-clinical or Phase 1 data only). Really? What this means is that the drug or technology looks good in mice, rats, or dogs, etc, but there is no smidgen of evidence that it will work in humans. That's what is called an appitite for RISK!
Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither Philstockworld, LLC (PSW) nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.